{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:53:16Z","timestamp":1792608796203,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00747-3","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:41:09Z","timestamp":1755862869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Willingness to use long-acting injectable pre-exposure prophylaxis among key populations at a large HIV prevention clinic in Kampala, Uganda: a cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Jonathan Derrick","family":"Lukubuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Katana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal","family":"Baguma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kaguta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Nambatya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kyambadde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Muwonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mujugira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Agnes Laker","family":"Odongpiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"747_CR1","unstructured":"UNAIDS, Global HIV. & AIDS statistics \u2014 Fact sheet 2023 [updated 31st August, 20238th October, 2023]. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet#:~:text=In%202022%2C%20there%20were%2039.0%20million%20%5B33.1%20million%E2%80%9345.7,people%20living%20with%20HIV%20were%20women%20and%20girls"},{"key":"747_CR2","unstructured":"Poku O, Intersecting, Vulnerabilities:, The implications of disclosure, Stigma, And mental health for individuals living with HIV in Sub-Saharan Africa. Johns Hopkins University; 2021."},{"issue":"1","key":"747_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1874613601610010034","volume":"10","author":"ABM Kharsany","year":"2016","unstructured":"Kharsany ABM, Karim QA. HIV infection and AIDS in Sub-Saharan Africa: current status, challenges and opportunities. Open AIDS J. 2016;10(1):34\u201348.","journal-title":"Open AIDS J"},{"key":"747_CR4","unstructured":"Street C, World Aids. Day 2022 2022 [Available from: https:\/\/coinstreet.org\/latest\/world-aids-day-2022"},{"key":"747_CR5","unstructured":"UAC. The 2023 joint AIDS review report. In: President Oot, editor.; 2023."},{"key":"747_CR6","unstructured":"KMCC. Long distance truck drivers and HIV\/AIDS in Uganda: Synthesis of information and evidence to inform the response - Abridged report| Eldis. 2014."},{"issue":"3","key":"747_CR7","doi-asserted-by":"publisher","first-page":"e12118","DOI":"10.2196\/12118","volume":"5","author":"RH Doshi","year":"2019","unstructured":"Doshi RH, Apodaca K, Ogwal M, Bain R, Amene E, Kiyingi H, et al. Estimating the size of key populations in Kampala, Uganda: 3-Source Capture-Recapture study. JMIR Public Health Surveill. 2019;5(3):e12118.","journal-title":"JMIR Public Health Surveill"},{"key":"747_CR8","doi-asserted-by":"crossref","unstructured":"Okal J, Geibel S, Muraguri N, Musyoki H, Tun W, Broz D et al. Estimates of the size of key populations at risk for HIV infection: men who have sex with men, female sex workers and injecting drug users in Nairobi, Kenya. Sexually transmitted infections. 2013.","DOI":"10.1136\/sextrans-2013-051071"},{"key":"747_CR9","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2016. 2016."},{"key":"747_CR10","unstructured":"AVAC. The Global PrEP Tracker 2022 [Available from: https:\/\/data.prepwatch.org\/"},{"key":"747_CR11","unstructured":"MoH-Uganda. Technical Guidance on Pre-Exposure Prophylaxis (PrEP) for Persons at Substantial Risk of HIV Infection in Uganda. 2022."},{"key":"747_CR12","unstructured":"Ministry of Health. Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda. 2022."},{"key":"747_CR13","unstructured":"UAC, National HIV, Priority Action AIDS. Plan 2020\/2021\u20132022\/2023: Ending the HIV and AIDS epidemic: Communities at the forefront: Kampala: Uganda AIDS Commission; 2020."},{"key":"747_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-016-3573-0","volume":"16","author":"T Kakaire","year":"2016","unstructured":"Kakaire T, Schlech W, Coutinho A, Brough R, Parkes-Ratanshi R. The future of financing for HIV services in Uganda and the wider sub-Saharan Africa region: should we ask patients to contribute to the cost of their care? BMC Public Health. 2016;16:1\u20135.","journal-title":"BMC Public Health"},{"issue":"12","key":"747_CR15","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1097\/QAD.0000000000002598","volume":"34","author":"K Stankevitz","year":"2020","unstructured":"Stankevitz K, Grant H, Lloyd J, Gomez GB, Kripke K, Torjesen K, et al. Oral preexposure prophylaxis continuation, measurement and reporting. Aids. 2020;34(12):1801\u201311.","journal-title":"Aids"},{"issue":"4","key":"747_CR16","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9(4):e254\u201368.","journal-title":"Lancet HIV"},{"issue":"4","key":"747_CR17","doi-asserted-by":"publisher","first-page":"e0228620","DOI":"10.1371\/journal.pone.0228620","volume":"15","author":"D Pillay","year":"2020","unstructured":"Pillay D, Stankevitz K, Lanham M, Ridgeway K, Murire M, Briedenhann E, et al. Factors influencing uptake, continuation, and discontinuation of oral PrEP among clients at sex worker and MSM facilities in South Africa. PLoS ONE. 2020;15(4):e0228620.","journal-title":"PLoS ONE"},{"key":"747_CR18","unstructured":"Were D, Mukui I, Helgah M. Characterization of early adopters in a national oral pre-exposure prophylaxis (PrEP) scale-up program in Kenya. HIV Research for Prevention (R4P). 2018."},{"key":"747_CR19","unstructured":"Albert L, Caitlin T, Sean A, Kenneth C, Edward G, Marguerita L, editors. Substantial gaps in the PrEP continuum among transwomen compared with MSM in San Francisco. HIV Research for Prevention Conference; 2018."},{"issue":"5","key":"747_CR20","doi-asserted-by":"publisher","first-page":"e25909","DOI":"10.1002\/jia2.25909","volume":"25","author":"Y Mayanja","year":"2022","unstructured":"Mayanja Y, Kamacooko O, Lunkuse JF, Muturi-Kioi V, Buzibye A, Omali D, et al. Oral pre\u2010exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study. J Int AIDS Soc. 2022;25(5):e25909.","journal-title":"J Int AIDS Soc"},{"issue":"466","key":"747_CR21","first-page":"2","volume":"6","author":"L Mobula","year":"2015","unstructured":"Mobula L, Barnhart M, Malati C, Rakhmanina N, Minior T, Amzel A, et al. Long-acting, injectable antiretroviral therapy for the management of HIV infection: an update on a potential game-changer. J AIDS Clin Res. 2015;6(466):2.","journal-title":"J AIDS Clin Res"},{"issue":"7","key":"747_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"issue":"10337","key":"747_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389.","journal-title":"Lancet"},{"key":"747_CR24","unstructured":"Gus Cairns. Why is the roll-out of injectable PrEP taking so long? AIDSMAP; 2024 [Available from: https:\/\/www.aidsmap.com\/news\/mar-2024\/why-roll-out-injectable-prep-taking-so-long"},{"key":"747_CR25","unstructured":"WHO. Prequalificatin of Medical Products: World Health Organisation. 2023 [Available from: https:\/\/extranet.who.int\/prequal\/"},{"key":"747_CR26","unstructured":"MARPI. Welcome to Most At Risk Populations Initiative (MARPI) 2024 [Available from: https:\/\/marpi.org\/"},{"key":"747_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-34","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance\u2013a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med Res Methodol. 2014;14:1\u201312.","journal-title":"BMC Med Res Methodol"},{"key":"747_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-120","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14:1\u201313.","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"747_CR29","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.2105\/AJPH.2006.088682","volume":"97","author":"SA Parikh","year":"2007","unstructured":"Parikh SA. The political economy of marriage and HIV: the ABC approach,safe infidelity, and managing moral risk in Uganda. Am J Public Health. 2007;97(7):1198\u2013208.","journal-title":"Am J Public Health"},{"issue":"1","key":"747_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10461-022-03769-4","volume":"27","author":"D Faini","year":"2023","unstructured":"Faini D, Munseri P, Sandstrom E, Hanson C, Bakari M. Awareness, willingness and use of HIV pre-exposure prophylaxis among female sex workers living in Dar-es-Salaam, Tanzania. AIDS Behav. 2023;27(1):335\u201343.","journal-title":"AIDS Behav"},{"key":"747_CR31","doi-asserted-by":"publisher","first-page":"108058","DOI":"10.1016\/j.jsat.2020.108058","volume":"117","author":"R Shrestha","year":"2020","unstructured":"Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. J Subst Abuse Treat. 2020;117:108058.","journal-title":"J Subst Abuse Treat"},{"key":"747_CR32","doi-asserted-by":"crossref","unstructured":"Ogunbajo A, Tsai AC, Kanki PJ, Mayer KH. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa. AIDS and Behavior 2022;26(7):2363-75.","DOI":"10.1007\/s10461-022-03575-y"},{"issue":"3","key":"747_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/COH.0000000000000734","volume":"17","author":"O Sued","year":"2022","unstructured":"Sued O, Nardi N, Spadaccini L. Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review. Curr Opin HIV AIDS. 2022;17(3):145\u201361.","journal-title":"Curr Opin HIV AIDS"},{"key":"747_CR34","doi-asserted-by":"crossref","unstructured":"Lunkuse JF, Kamacooko O, Muturi-Kioi V, Chinyenze K, Kuteesa MO, Price MA et al. Low awareness of oral and injectable PrEP among high-risk adolescent girls and young women in Kampala, Uganda. BMC Infect Dis. 2022;22(1).","DOI":"10.1186\/s12879-022-07398-z"},{"key":"747_CR35","doi-asserted-by":"crossref","unstructured":"Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical trial (HPTN 076). Afr J Reprod Gynaecol Endoscopy. 2019;22(10).","DOI":"10.1002\/jia2.25408"},{"issue":"4","key":"747_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/15284336.2018.1511346","volume":"19","author":"MI Murray","year":"2018","unstructured":"Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, et al. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: patient perspectives from the ECLAIR trial. HIV Clin Trial. 2018;19(4):129\u201338.","journal-title":"HIV Clin Trial"},{"key":"747_CR37","doi-asserted-by":"crossref","unstructured":"Braz Junior R, Cesar G, Amianti C, Bandeira L, Da Silva A, Motta-Castro A. Behind Prep decisions: Understanding user patterns and discontinuation factors in Real-World. AIDS Behav. 2024;1\u201311.","DOI":"10.1007\/s10461-024-04383-2"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00747-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:58:15Z","timestamp":1757480295000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00747-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00747-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4719964\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and permission to conduct this study were obtained from the School of Health Sciences Institutional Research Board (Protocol number\u2013 MAKSHSREC-2021-180). Written informed consent was obtained from study participants before the commencement of the study activities after explaining the purpose of the study and possible benefits. Before the investigation, approval to conduct research at the MARPI clinic was obtained. Respondents\u2019 Participation was voluntary, and the identity of the respondents was not disclosed. All information given as a contribution to the study was handled with confidentiality, kept under lock and key, and with password protection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}